González-Moreno, Juan
Losada-López, Inés
Cisneros-Barroso, Eugenia
Garcia-Pavia, Pablo
González-Costello, José
Muñoz-Beamud, Francisco
Campistol, Josep Maria
Fernandez-Torron, Roberto
Chapman, Doug
Amass, Leslie
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
https://doi.org/10.1007/s40120-021-00267-y
Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
https://doi.org/10.1007/s40119-022-00265-7
Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS
https://doi.org/10.1007/s40119-021-00226-6
Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey
https://doi.org/10.1007/s40119-023-00344-3
A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy
https://doi.org/10.1080/13506129.2019.1643714
The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology
https://doi.org/10.1185/03007995.2012.754349
THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
https://doi.org/10.1185/03007995.2012.754348
Funding for this research was provided by:
Pfizer
Article History
Received: 2 June 2021
Accepted: 13 July 2021
First Online: 30 July 2021